is weighing an acquisition of US drugmaker , people familiar with the matter said, in what would be the largest biopharma deal in years. Paris-based Sanofi is speaking with advisers as it studies a potential deal for Insmed, according to the people, who asked not to be identified discussing confidential information. Shares in Insmed have fallen about 40% over the last 12 months, giving the company a market value of around $26.6 billion.
Michelle F. Davis
Verified
Senior Deals Reporter @Bloomberg News. Cover M&A across sectors w/ focus on health, media, telco, consumer. Tips: mdavis194@bloomberg.net | Telegram @mdavis194
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Michelle F.
Contact Michelle F., search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack